FDA Warning Letter due to Non-Compliance with Specifications

Recommendation
13-15 May 2025
Vienna, Austria
Practical Approaches for USP General Chapter <1058> Compliance in the QC Laboratory
This FDA Warning Letter issued to Indian drug manufacturer Kim Chemicals Private Ltd. on 16 October, 2017, is based on an FDA inspection conducted in July 2017.
The FDA criticised that not all drug products and the active substances they contained had been tested for compliance with their specifications before release. Some batches were distributed to the USA even though the active ingredient content was out of specification (OOS). They had simply copied values from old certificates of analysis to the new batches' certificates of analysis.
In quality control, there were no written procedures in the form of SOPs for a number of critical processes. This included requirements for:
- Complaint handling
- Recalls
- Investigation of OOS results
- Deviation investigation
- Returns
- Stability
Furthermore, no data could be supplied to verify the values listed in the analysis certificates.
The performed tests had been noted down in a piece of paper and then transferred to the certificate of analysis, while the piece of paper was simply discarded. Also, there were no records on how the calculation had been performed.
The FDA therefore concluded that the company's quality management system is not fit to verify the accuracy and integrity of data.
Source: FDA Warning Letter to Kim Chemicals Private Ltd.
Related GMP News
12.02.2025USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
12.02.2025FDA Warning Letter: Focus on Quality Control of APIs and Excipients
29.01.2025Revision of USP <1032> Design and Development of Biological Assays
23.01.2025English Translation of Supplement II to the Japanese Pharmacopoeia (JP18) Published
23.01.2025How to keep Analytical Systems Current and Compliant
23.01.2025FDA 483s due to Deficiencies in the Stability Program: Evaluation of Fiscal Year 2024